If you have been reading about rodent models and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Aya Majzoub, Amnesty International's Deputy Regional Director for the Middle East and North Africa, described the attack as a violation of international law that needed to be investigated as a war crime, and that it "seriously endangered the lives of civilians, many of whom were hospitalized and displaced, and whose homes and cars caught fire". Lebanese state media reported that Dhayra and other areas along the western section of the border came under "continuous" bombardment overnight. In the early morning it was reported that multiple people were suffering from symptoms of suffocation after the IDF allegedly fired white phosphorus shells on the village. Three people were injured after an anti-tank missile from Lebanon landed in the Israeli town of Metula. Hezbollah announced that five of its members were killed on the same day but it was unclear if any had involvement in the border infiltration. On 19 October, the Lebanese Armed Forces said that one person was killed and another injured after a group of seven Iranian journalists were targeted with machine guns by Israel, although Iranian state media denied the claim and said that all its journalists were "alive and healthy". UNIFIL peacekeepers said that one person was killed when civilians were caught in a cross-fire at the border. The Lebanese Army requested assistance by UNIFIL to de-escalate the situation, and Israel was asked to suspend fire to allow the rescue operation to proceed.
The mean lifetime of 238U (or any nuclide) is the half-life divided by ln(2) ≈ 0.693 (or multiplied by 1/ln(2) ≈ 1.443), which is about 2×1017 seconds, so 1 mole of 238U emits 3×106 alpha particles per second, producing the same number of thorium-234 atoms. In a closed system an equilibrium would be reached in which all members except the stable end-product have fixed ratios to one another, but in slowly decreasing amount. The amount of 206Pb will increase accordingly while that of 238U decreases; all steps in the decay chain have this same rate of 3×106 decayed particles per second per mole 238U. While 238U is minimally radioactive, its decay products, thorium-234 and protactinium-234, are beta particle emitters with half-lives of about 20 days and one minute respectively. Protactinium-234 decays to uranium-234, which has a half-life of hundreds of millennia, and this isotope does not reach an equilibrium concentration for a very long time. When the two first isotopes in the decay chain reach their relatively small equilibrium concentrations, a sample of initially pure 238U will emit three times the radiation due to 238U itself, and most of this radiation is beta particles. As already touched upon above, when starting with pure 238U, within a human timescale the equilibrium applies for the first three steps in the decay chain only. Thus, for one mole of 238U, 3×106 times per second one alpha and two beta particles and a gamma ray are produced, together 6.7 MeV, for a rate of 3 μW.
Genetic factors may be the most significant cause of autism. Early studies of twins had estimated heritability to be over 90%, meaning that genetics explains over 90% of whether a child will develop autism. This may be an overestimation, as later twin studies estimate the heritability at between 60 and 90%. Evidence so far still suggests a strong genetic component, with one of the largest and most recent studies estimating the heritability at 83%. Many of the non-autistic co-twins had learning or social disabilities. For adult siblings, the probability of having one or more features constitutive of the broader autism phenotype may be as high as 30%. In spite of the strong heritability, most cases of autism occur sporadically with no recent evidence of family history. It has been hypothesized that spontaneous de novo mutations in the sperm or egg contribute to the likelihood of developing autism. Additionally, mutations of the Fragile X Messenger Ribonucleoprotein 1 (FMR1) which cause fragile X syndrome, one of the most common causes of intellectual disability and autism, have been linked to the early cessation of reproductive functions of female carriers in the gene. This substantiates the notion that those with autism are more likely to be infertile, weakening the heritability of the disorder. Also, the likelihood of having a child develop autism generally increases with advancing parental age, and mutations in sperm gradually accumulate throughout a man's life.
Sources: en.wikipedia.org
== Adverse effects == The most common adverse side effects of clonidine are dry mouth and sedation. Many side effects are dose-related and tend to diminish with tolerance that develops from continued use. For the same reason that clonidine has efficacy for treating hypertension, hypotension (i.e., low blood pressure) and bradycardia (i.e., slow heart rate) are predictable dose-dependent effects. However, with overdose in children, the degree of central nervous system depression does not clearly correlate with the ingested dose.
=== Stimulus-secretion coupling === In response to, for instance, a rise in the plasma sodium concentration, vasopressin neurons also discharge action potentials in bursts, but these bursts are much longer and are less intense than the bursts displayed by oxytocin neurons, and the bursts in vasopressin cells are not synchronised. It seemed strange that the vasopressin cells should fire in bursts. As the activity of the vasopressin cells is not synchronised, the overall level of vasopressin secretion into the blood is continuous, not pulsatile. Richard Dyball and his co-workers speculated that this pattern of activity, called "phasic firing", might be particularly effective for causing vasopressin secretion. They showed this to be the case by studying vasopressin secretion from the isolated posterior pituitary gland in vitro. They found that vasopressin secretion could be evoked by electrical stimulus pulses applied to the gland, and that much more hormone was released by a phasic pattern of stimulation than by a continuous pattern of stimulation. These experiments led to interest in "stimulus-secretion coupling" - the relationship between electrical activity and secretion. Supraoptic neurons are unusual because of the large amounts of peptide that they secrete, and because they secrete the peptides into the blood. However, many neurons in the brain, and especially in the hypothalamus, synthesize peptides. It is now thought that bursts of electrical activity might be generally important for releasing large amounts of peptide from peptide-secreting neurons.
Federated States of Micronesia - Scouting in the Federated States of Micronesia* - Aloha Council of the Boy Scouts of America Marshall Islands - Scouting in the Marshall Islands* - Aloha Council of the Boy Scouts of America Palau - Scouting in Palau* - Aloha Council of the Boy Scouts of America Served by The Scout Association (UK)
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.